ATE156711T1 - Nicht-zellzahlverringernde cd4-spezifische monoklonale antikörper zur behandlung von insulinabhängigem diabetes mellitus (iddm) - Google Patents

Nicht-zellzahlverringernde cd4-spezifische monoklonale antikörper zur behandlung von insulinabhängigem diabetes mellitus (iddm)

Info

Publication number
ATE156711T1
ATE156711T1 AT92902288T AT92902288T ATE156711T1 AT E156711 T1 ATE156711 T1 AT E156711T1 AT 92902288 T AT92902288 T AT 92902288T AT 92902288 T AT92902288 T AT 92902288T AT E156711 T1 ATE156711 T1 AT E156711T1
Authority
AT
Austria
Prior art keywords
insulin
treatment
monoclonal antibodies
iddm
diabetes mellitus
Prior art date
Application number
AT92902288T
Other languages
English (en)
Inventor
Anne Cooke
Herman Waldmann
Original Assignee
Univ London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ London filed Critical Univ London
Application granted granted Critical
Publication of ATE156711T1 publication Critical patent/ATE156711T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT92902288T 1991-01-14 1992-01-14 Nicht-zellzahlverringernde cd4-spezifische monoklonale antikörper zur behandlung von insulinabhängigem diabetes mellitus (iddm) ATE156711T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919100741A GB9100741D0 (en) 1991-01-14 1991-01-14 Treatment of disease

Publications (1)

Publication Number Publication Date
ATE156711T1 true ATE156711T1 (de) 1997-08-15

Family

ID=10688399

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92902288T ATE156711T1 (de) 1991-01-14 1992-01-14 Nicht-zellzahlverringernde cd4-spezifische monoklonale antikörper zur behandlung von insulinabhängigem diabetes mellitus (iddm)

Country Status (10)

Country Link
US (1) US5670150A (de)
EP (1) EP0567490B1 (de)
JP (1) JP3168005B2 (de)
AT (1) ATE156711T1 (de)
AU (1) AU668081B2 (de)
CA (1) CA2100462C (de)
DE (1) DE69221605T2 (de)
ES (1) ES2106169T3 (de)
GB (1) GB9100741D0 (de)
WO (1) WO1992011869A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080112300A (ko) * 2006-03-16 2008-12-24 제넨테크, 인크. Ｃｄ4 항체를 사용하여 루푸스를 치료하는 방법
WO2010009129A2 (en) * 2008-07-15 2010-01-21 Genentech, Inc. Methods of treating autoimmune diseases using cd4 antibodies
US20160158352A1 (en) * 2013-07-10 2016-06-09 The United States of America, as represented by the Secretary, Department of Health & Human Servic Apoptotic cell-mediated induction of antigen specific regulatory t-cells for the therapy of autoimmune diseases in animals and humans
JP7321465B2 (ja) * 2018-04-17 2023-08-07 ナショナル キャンサー センター 枯渇性抗ｃｄ４モノクローナル抗体を含む抗癌ｔ細胞治療剤補助用組成物及びその用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0380018B1 (de) * 1989-01-23 1995-07-19 Abbott Laboratories Monoklonale Antikörper von Ratten gegen menschliche Antigene und Verfahren zu deren Herstellung
GB8912497D0 (en) * 1989-05-31 1989-07-19 Cobbold Stephen P Monoclonal antibodies

Also Published As

Publication number Publication date
JP3168005B2 (ja) 2001-05-21
WO1992011869A1 (en) 1992-07-23
GB9100741D0 (en) 1991-02-27
EP0567490A1 (de) 1993-11-03
US5670150A (en) 1997-09-23
CA2100462A1 (en) 1992-07-15
ES2106169T3 (es) 1997-11-01
DE69221605D1 (de) 1997-09-18
AU668081B2 (en) 1996-04-26
CA2100462C (en) 2003-06-17
JPH06504283A (ja) 1994-05-19
EP0567490B1 (de) 1997-08-13
DE69221605T2 (de) 1998-02-12
AU1164792A (en) 1992-08-17

Similar Documents

Publication Publication Date Title
PT724456E (pt) Anticorpos contra cd4
DK0617575T3 (da) Indretning til dyrkning af planter
DE69109560D1 (de) Fungizide Zusammensetzung zur Behandlung von Saatgut.
MY111682A (en) Altered antibodies and their preparations.
HUP9802212A2 (hu) Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok
GR3025644T3 (en) Improved monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use
DK0807125T3 (da) Monoklonale antistoffer mod CD6 til behandling og diagnosticering af psoriasis
ATE395081T1 (de) Lo-cd2a antikörper und dessen verwendungen zur hemmung von t-zell aktivierung und wachstum
DE69019345D1 (de) Zusammensetzung zur behandlung von samen.
FI98510B (fi) Vateriitti ja menetelmä sen valmistamiseksi
DE59104044D1 (de) Vorrichtung für den Transport von Substraten.
DE3162128D1 (en) Biologically active compounds, their obtention from human casein and compositions containing them
AU2002223462A1 (en) Use of cd28-specific monoclonal antibodies for stimulating blood cells that lackcd28
FI951511A0 (fi) IL-10:n käyttö insuliinista riippuvan diabetes mellituksen ennaltaestoon tai hoitoon
DK0802924T3 (da) Lægemiddel til forlænget immunsuppression og eliminering af tumorceller
ATE206621T1 (de) Il-8 antagonisten zur behandlung von asthma
ATE156711T1 (de) Nicht-zellzahlverringernde cd4-spezifische monoklonale antikörper zur behandlung von insulinabhängigem diabetes mellitus (iddm)
DK0561846T3 (da) 4,5-dihydroxy- og 4,5,8-trihydroxy-9,10-dihydro-9,10-dioxo-2-anthracencarboxylsyre-dicarbonater og -urethaner med terapeutisk virkning
DE69633393D1 (de) Mitteln zur behandlung von auto-immun krankheiten
ATE205531T1 (de) Lo-cd2a antikörper und dessen verwendung zur inhibition von t-zell-aktivierung und -wachstum
DE3585049D1 (de) Monoklonale antikoerper.
HUP0104842A2 (hu) Vakcina
EP0585364A4 (de) Das durch den monoklonalen menschlichen antikörper 81av78 erkannte antigen ctaa 81av78.
DE3785555D1 (de) Verwendung von guaifenesin zur behandlung urologischer beschwerden.
ATE107165T1 (de) Verwendung von macrolactonen als antiallergica.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties